Drug Trial Radar · NCT07390955
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
Mar 19, 2026
Primary completion
Aug 30, 2027
Study completion Aug 30, 2027
Sponsor
- Sponsor type
- NIH
- Collaborators
- National Institutes of Health (NIH); Department of Health and Human Services
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity). The expectation is that ePGT121v1-LS, whether given alone or with PGDM1400LS and VRC07-523LS, by IV or SC, will be safe in generally healthy adults and that the antibodies will not interfere with each other when used together. Approximately 83 volunteers in overall good health and without HIV-1 will be enrolled into two parts (A and B). Part A has six groups. In Groups 1-3, participants will get ePGT121v1-LS given by IV at one of three dose levels: 5 mg/kg, 20 mg/kg, or 40 mg/kg. In Groups 4-6, participants will receive three antibodies-first ePGT121v1-LS, then PGDM1400LS and VRC07-523LS-given by IV at two separate visits that are 24 weeks apart. The total study duration for participants in Part A is 48 weeks of scheduled clinic visits. Part B has two groups. In Group 7, people will get ePGT121v1-LS as SC shots at two visits 12 weeks apart. Each visit will give a total of 375 mg, split into three injections of 125 mg each. In Group 8, people will also have two visits 12 weeks apart and will receive three antibodies as SC shots in this order: first ePGT121v1-LS (125 mg), then PGDM1400LS (100 mg), and then VRC07-523LS (100 mg). The total study duration for participants in Part B is 24 weeks of scheduled clinic visits.
Conditions
- HIV
Interventions
ePGT121v1-LS (IV)Biological
Intravenous infusion (IV)
PGDM1400LS (IV)Biological
IV infusion
VRC07-523LS (IV)Biological
IV infusion
ePGT121v1-LS (SC)Biological
Subcutaneous (SC) injection
PGDM1400LS (SC)Biological
SC injection
VRC07-523LS (SC)Biological
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 48
- Part B: Number of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 24
- Part A: Percentage of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 48
- Part B: Percentage of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 24
- Part A: Number of participants with solicited systemic AEsTime frame: Baseline through Week 48
- Part B: Number of participants with solicited systemic AEsTime frame: Baseline through Week 24
- Part A: Percentage of participants with solicited systemic AEsTime frame: Baseline through Week 48
- Part B: Percentage of participants with solicited systemic AEsTime frame: Baseline through Week 24
- Part A: Percentage of participants with safety laboratory abnormalities meeting grade 1 AE criteria or aboveTime frame: Baseline through Week 48
- Part B: Percentage of participants with safety laboratory abnormalities meeting grade 1 AE criteria or aboveTime frame: Baseline through Week 24
- Part A: Number of participants with unsolicited AEsTime frame: Baseline through Week 48
- Part B: Number of participants with unsolicited AEsTime frame: Baseline through Week 24
- Part A: Percentage of participants with unsolicited AEsTime frame: Baseline through Week 48
- Part B: Percentage of participants with unsolicited AEsTime frame: Baseline through Week 24
- Part A: Number of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 48
- Part B: Number of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 24
- Part A: Percentage of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 48
- Part B: Percentage of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 24
- Part A: Number of participants who discontinue study product administrationTime frame: Baseline through Week 48
- Part B: Number of participants who discontinue study product administrationTime frame: Baseline through Week 24
- Part A: Percentage of participants who discontinue study product administrationTime frame: Baseline through Week 48
- Part B: Percentage of participants who discontinue study product administrationTime frame: Baseline through Week 24
- Part A: Number of participants who terminate the study earlyTime frame: Baseline through Week 48
- Part B: Number of participants who terminate the study earlyTime frame: Baseline through Week 24
- Part A: Percentage of participants who terminate the study earlyTime frame: Baseline through Week 48
- Part B: Percentage of participants who terminate the study earlyTime frame: Baseline through Week 24
- Part A: Serum Concentration of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: Serum Concentration of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: Serum Concentration of PGDM1400LSTime frame: Baseline through Week 48
- Part B: Serum Concentration of PGDM1400LSTime frame: Baseline through Week 24
- Part A: Serum Concentration of VRC07-523LSTime frame: Baseline through Week 48
- Part B: Serum Concentration of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Area Under the Concentration-Time Curve (AUC) of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: AUC of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: AUC of PGDM1400LSTime frame: Baseline through Week 48
- Part B: AUC of PGDM1400LSTime frame: Baseline through Week 24
- Part A: AUC of VRC07-523LSTime frame: Baseline through Week 48
- Part B: AUC of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Maximum Observed Concentration (Cmax) of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: Cmax of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: Cmax of PGDM1400LSTime frame: Baseline through Week 48
- Part B: Cmax of PGDM1400LSTime frame: Baseline through Week 24
- Part A: Cmax of VRC07-523LSTime frame: Baseline through Week 48
- Part B: Cmax of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Time to Maximum Concentration (Tmax) of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: Tmax of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: Tmax of PGDM1400LSTime frame: Baseline through Week 48
- Part B: Tmax of PGDM1400LSTime frame: Baseline through Week 24
- Part A: Tmax of VRC07-523LSTime frame: Baseline through Week 48
- Part B: Tmax of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Clearance (CL) of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: CL of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: CL of PGDM1400LSTime frame: Baseline through Week 48
- Part B: CL of PGDM1400LSTime frame: Baseline through Week 24
- Part A: CL of VRC07-523LSTime frame: Baseline through Week 48
- Part B: CL of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Volume of Distribution (Vd) of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: Vd of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: Vd of PGDM1400LSTime frame: Baseline through Week 48
- Part B: Vd of PGDM1400LSTime frame: Baseline through Week 24
- Part A: Vd of VRC07-523LSTime frame: Baseline through Week 48
- Part B: Vd of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Terminal Elimination Rate Constant (λz) of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: λz of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: λz of PGDM1400LSTime frame: Baseline through Week 48
- Part B: λz of PGDM1400LSTime frame: Baseline through Week 24
- Part A: λz of VRC07-523LSTime frame: Baseline through Week 48
- Part B: λz of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Terminal Half-life (T1/2) of ePGT121v1-LSTime frame: Baseline through Week 48
- Part B: T1/2 of ePGT121v1-LSTime frame: Baseline through Week 24
- Part A: T1/2 of PGDM1400LSTime frame: Baseline through Week 48
- Part B: T1/2 of PGDM1400LSTime frame: Baseline through Week 24
- Part A: T1/2 of VRC07-523LSTime frame: Baseline through Week 48
- Part B: T1/2 of VRC07-523LSTime frame: Baseline through Week 24
- Part A: Area Under the Magnitude-Breadth Curve (AUC-MB)Time frame: Baseline through Week 48
- Part B: AUC-MBTime frame: Baseline through Week 24
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Alabama CRS (Site ID: 31788)
Birmingham, Alabama · Recruiting
Bridge HIV CRS (Site ID: 30305)
San Francisco, California · Recruiting
The Ponce de Leon Center CRS (Site ID: 5802)
Atlanta, Georgia · Recruiting
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) (Site ID: 30007)
Boston, Massachusetts · Recruiting
Penn Prevention CRS (Site ID: 30310)
Philadelphia, Pennsylvania · Recruiting
Vanderbilt Vaccine (VV) CRS (Site ID: 30352)
Nashville, Tennessee · Recruiting
Houston Advancing Research Team CRS (Site ID: 31473)
Houston, Texas · Recruiting
Via Libre CRS (Site ID: 31909)
Lima Cercado, Lima region, Peru · Not yet recruiting
Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) (Site ID: 31970)
Bellavista, Provincia Constitucional del Callao, Peru · Not yet recruiting
Seke South CRS (Site ID: 30294)
Chitungwiza, Zimbabwe · Not yet recruiting
Spilhaus CRS (Site ID: 30314)
Harare, Zimbabwe · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.